Rilvegostomig

Multispecific antibody

Also known as AZD2936

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-12-28.

Also in development:Biliary Tract Cancer · Phase 3Hepatocellular Carcinoma · Phase 3Gastric Cancer · Phase 3Urothelial Carcinoma · Phase 3Endometrial Cancer · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (13)
Biliary Tract Cancer
Endometrial Cancer
Gastric Cancer
NCT07431281 · AstraZeneca
2026-02-03 – 2031-10-27 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
What this study did
NCT06764875 · AstraZeneca
2025-03-01 – 2030-12-09 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
Hepatocellular Carcinoma
NCT06921785 · AstraZeneca
2025-05-06 – 2030-03-15 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
Urothelial Carcinoma
NCT07720284 · AstraZeneca
2026-07-16 – 2032-11-23 · High-risk Muscle Invasive Urothelial Carcinoma
What this study did
Phase 2 (14)
Biliary Tract Cancer
NCT05489211 · AstraZeneca
2022-09-06 – 2027-10-01 · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
What this study did
Gastric Cancer
NCT07788664 · Vall d'Hebron Institute of Oncology
2026-12-01 – 2030-06-01 · Advanced Gastric Cancer
What this study did
NCT06630130 · Jeeyun Lee
2025-01-22 – 2029-06-30 · Stomach Neoplasms
What this study did
NCT05702229 · AstraZeneca
2023-01-16 – 2029-05-31 · Gastric Cancer
What this study did
NCT04379596 · AstraZeneca
2020-06-03 – 2027-05-04 · Gastric Cancer
What this study did
Hepatocellular Carcinoma
NCT05775159 · AstraZeneca
2023-04-24 – 2027-10-28 · Hepatocellular Carcinoma, Biliary Tract Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05061550 · AstraZeneca
2022-04-14 – 2030-05-28 · Non-small Cell Lung Cancer
What this study did
NCT07098338 · AstraZeneca
2025-08-07 – 2029-04-06 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07069712 · AstraZeneca
2025-07-17 – 2029-07-16 · Gastroesophageal Adenocarcinoma
What this study did
NCT07128290 · Federation Francophone de Cancerologie Digestive
2025-10-30 – 2029-04-30 · Intrahepatic Cholangiocarcinoma (Icc)
What this study did
NCT06569225 · University Health Network, Toronto
2024-12-15 – 2028-12-31 · Cholangiocarcinoma Resectable
What this study did
NCT05414032 · University Health Network, Toronto
2023-07-12 – 2028-07 · Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
What this study did
NCT03741426 · CCTU- Cancer Theme
2020-07-27 – 2027-12-30 · Renal Cell Cancer
What this study did
Phase 1/2 (5)
Gastric Cancer
NCT06005493 · AstraZeneca
2023-07-11 – 2029-03-16 · Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07115043 · AstraZeneca
2025-07-29 – 2029-10-02 · Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
What this study did
NCT06996782 · AstraZeneca
2025-11-24 – 2029-02-23 · Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT04995523 · AstraZeneca
2021-09-14 – 2028-06-01 · Non-Small-Cell Lung Carcinoma
What this study did
NCT05123482 · AstraZeneca
2021-10-18 – 2027-09-29 · Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
What this study did
Phase 1 (6)
Non-Small Cell Lung Cancer
NCT04686305 · AstraZeneca
2021-03-09 – 2027-06-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT04612751 · AstraZeneca
2021-02-02 – 2027-05-04 · Advanced or Metastatic NSCLC
What this study did
NCT03819465 · AstraZeneca
2018-12-27 – 2026-07-01 · Metastatic Non-Small Cell Lung Cancer (NSCLC)
What this study did
Other / comorbidity
NCT04541108 · Presage Biosciences
2021-07-26 – 2031-12 · Solid Tumor
What this study did
NCT06366451 · Presage Biosciences
2024-05-22 – 2026-03-25 · Head and Neck Squamous Cell Carcinoma
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Biliary Tract Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rilvegostomig: this drugPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6)
ZanidatamabApprovedMultispecific antibodyHER2Weak signal
NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023)
Futibatinib (Lytgobi)Phase 3Small moleculeFGFR (FGFR1/2/3/4)not yet gradedNo reviewed efficacy summary in this indication
IvonescimabPhase 3Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
TovecimigPhase 2/3Multispecific antibodyDLL4 x VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RamucirumabPhase 2Monoclonal antibodyVEGFR2not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(33 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rilvegostomig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (10)
May 2027 (1)
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-05-04 · NCT04379596 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT04686305 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2027-07-19 · NCT07161414 · CT.gov ↗
What to watch
September 2027 (2)
Phase 2Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)Recruiting
Est. primary completion 2027-09 · NCT05414032 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-29 · NCT05123482 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2027-10-01 · NCT05489211 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2027-11-09 · NCT07069712 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-11-30 · NCT05702229 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Renal Cell CancerRecruiting
Est. primary completion 2027-12-30 · NCT03741426 · CT.gov ↗
What to watch
Phase 2Cholangiocarcinoma ResectableNot yet recruiting
Est. primary completion 2027-12-31 · NCT06569225 · CT.gov ↗
What to watch
2028 (3)
June 2028 (2)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-06-01 · NCT04995523 · CT.gov ↗
What to watch
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2028-06-12 · NCT06467357 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-10-30 · NCT06630130 · CT.gov ↗
What to watch
2029 (11)
January 2029 (2)
Phase 3Biliary Tract CancerActive not recruiting
Est. primary completion 2029-01-02 · NCT06109779 · CT.gov ↗
What to watch
Phase 3Endometrial CancerRecruiting
Est. primary completion 2029-01-19 · NCT06989112 · CT.gov ↗
What to watch
February 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-23 · NCT06996782 · CT.gov ↗
What to watch
March 2029 (1)
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2029-03-16 · NCT06005493 · CT.gov ↗
What to watch
April 2029 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-04-06 · NCT07098338 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2029-04-27 · NCT06764875 · CT.gov ↗
What to watch
Phase 2Intrahepatic Cholangiocarcinoma (Icc)Not yet recruiting
Est. primary completion 2029-04-30 · NCT07128290 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2029-07-31 · NCT07221253 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Gastric CancerRecruiting
Est. primary completion 2029-08-16 · NCT07431281 · CT.gov ↗
What to watch
October 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-10-02 · NCT07115043 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-12-28 · NCT06357533 · CT.gov ↗
What to watch
2030 (8)
January 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-01-17 · NCT06868277 · CT.gov ↗
What to watch
March 2030 (1)
Phase 3Hepatocellular CarcinomaRecruiting
Est. primary completion 2030-03-15 · NCT06921785 · CT.gov ↗
What to watch
May 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-05-28 · NCT05061550 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2030-06-01 · NCT07788664 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-07-01 · NCT06692738 · CT.gov ↗
What to watch
September 2030 (1)
Phase 3Urothelial CarcinomaRecruiting
Est. primary completion 2030-09-11 · NCT07720284 · CT.gov ↗
What to watch
November 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-11-18 · NCT06627647 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 1Solid TumorActive not recruiting
Est. primary completion 2031-12 · NCT04541108 · CT.gov ↗
What to watch

See the full readout calendar ↗